iRhythm’s 40% decline validates InvestingPro Fair Value analysis

iRhythm Technologies was flagged as 34.61% overvalued at $187.30 versus a calculated fair value of $122.47, and the stock later fell 39.68% to $112.97 by March 2026. The company still faces valuation pressure despite improved fundamentals, with revenue rising to $747.1 million and EBITDA losses narrowing to -$30.6 million; insiders sold shares and Truist/Canaccord cut price targets. Shares remain below the original entry point at $125.32 in April 2026.

Analysis

The key takeaway is not that valuation eventually mattered; it’s that the stock’s ownership base likely did the work of the re-rating. Once insiders and sell-side both moved to the same side of the boat, the name shifted from a “growth at any price” story to a crowded de-risking candidate, and that tends to compress multiples faster than modest operating improvement can offset. In other words, the market is still paying for a historical growth rate that the current margin profile does not support.

The second-order effect is on the rest of the ambulatory monitoring space: when one premium healthcare tech multiple de-rates, the market usually re-prices adjacent peers on the same EV/revenue framework, even if their execution is better. That creates a window where better-quality operators can be bought cheaper simply because the group’s narrative was damaged. The risk is that any additional insider selling or target cuts keep pressure on the stock for months, not days, because the valuation reset is doing the heavy lifting rather than an acute fundamental deterioration.

The contrarian read is that the move may still be underdone if revenue growth decelerates below the current guidance range or if margins stall again. A business with negative EBITDA is especially vulnerable to higher discount rates: even small changes in growth assumptions can justify large multiple compression. The flip side is that if the company prints a couple of quarters of clean execution and proves operating leverage, the stock can rebound sharply off a lower base because the bad news is now largely in the price.

Key Decisions for Investors

• Maintain a tactical short or underweight in IRTC into any strength over the next 4-8 weeks; risk/reward is favorable while the market is still digesting valuation-reset risk and insider-supply overhang.
• Use a call spread if you want bullish exposure: buy 3-6 month IRTC call spreads only after a post-earnings confirmation of margin improvement, because upside likely requires evidence of operating leverage rather than simple revenue growth.
• Pair trade: long a lower-multiple healthcare device name against short IRTC for 2-3 months; the relative-value setup benefits if the market continues rotating from high-multiple, cash-burning growth to profitable compounders.
• If IRTC falls back toward the prior fair-value zone, cover shorts and reassess for a mean-reversion long only if management demonstrates sustained EBITDA improvement for at least two consecutive quarters.
• Watch for any new insider sales or analyst target cuts as a trigger to add on weakness; those events would likely extend the de-rating window by another 1-2 quarters.